Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Liabilities and Shareholders Equity (2016 - 2025)

RedHill Biopharma has reported Liabilities and Shareholders Equity over the past 15 years, most recently at $25.3 million for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 40.47% to $25.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $83.8 million through Dec 2025, down 14.63% year-over-year, with the annual reading at $25.3 million for FY2025, 40.47% up from the prior year.
  • Liabilities and Shareholders Equity was $25.3 million for Q4 2025 at RedHill Biopharma, up from $18.4 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $220.1 million in Q1 2021 and troughed at $18.0 million in Q4 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $157.2 million (2022), against an average of $109.5 million.
  • Year-over-year, Liabilities and Shareholders Equity skyrocketed 53.42% in 2021 and then plummeted 85.49% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $181.2 million in 2021, then decreased by 12.32% to $158.9 million in 2022, then plummeted by 85.49% to $23.0 million in 2023, then fell by 21.71% to $18.0 million in 2024, then surged by 40.47% to $25.3 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Liabilities and Shareholders Equity are $25.3 million (Q4 2025), $18.4 million (Q2 2025), and $18.0 million (Q4 2024).